Global Health Limited (Medanta) Presents Investor Presentation for FY2026 Results
Global Health Limited (Medanta) reported FY2026 consolidated income of ₹45,089 million (up 19.6% YoY) and PAT of ₹5,541 million (up 15.1% YoY). Q4 FY2026 saw record revenue of ₹11,958 million (up 25.3% YoY). The company added 623 beds in FY2026 and plans over ₹45,000 million capex for future expansion.
The announcement details robust financial performance, significant capacity expansion, and strategic future growth plans, which are material for investors and stakeholders.
The company reported strong year-on-year growth in revenue and profit for both the full year and the fourth quarter, along with significant expansion plans and a recommended dividend.
Global Health Limited (Medanta) has released its Investor Presentation for the fourth quarter and financial year ended March 31, 2026. The presentation details the company's performance, strategic initiatives, and future outlook.
For the full fiscal year 2026, Medanta reported a consolidated total income of ₹45,089 million, a significant increase of 19.6% year-on-year. EBITDA (excluding Noida) grew by 18.6% to ₹11,343 million, maintaining healthy margins of 25.7%. Profit After Tax (PAT) stood at ₹5,541 million, reflecting a 15.1% year-on-year growth. The company added 623 beds during FY2026, a 20.5% increase, with major additions in Noida (382 beds), Patna (131 beds), and a new 110-bed hospital in Ranchi. In-patient volumes increased by 16.0% and out-patient volumes by 18.7%. The average revenue per occupied bed (ARPOB) grew by 6.1% to ₹66,550.
The Noida facility, inaugurated in November 2025, is now fully operational with 382 beds. In FY2026, it generated revenue of ₹906 million and an EBITDA loss of ₹783 million, with a trend of declining quarterly losses. Matured hospitals showed a 9.0% revenue growth, while developing hospitals (ex-Noida) reported a 29.2% revenue increase.
In the fourth quarter of FY2026, Medanta achieved its highest-ever quarterly total income of ₹11,958 million, a 25.3% year-on-year increase. EBITDA (excluding Noida) grew by 27.0% to ₹3,142 million with improved margins of 27.5%. PAT for the quarter was ₹1,417 million, a robust 39.7% increase year-on-year.
Looking ahead, Medanta has a robust pipeline of expansion projects, including new hospitals in Guwahati, Varanasi, Mumbai, and Delhi, with a planned capex of over ₹45,000 million over the next five years. The company also plans to establish a medical college and a guest house on its Gurugram campus.
The Board of Directors has recommended a final dividend of 25% on the face value of ₹2 per share, amounting to ₹0.50 per share.
What to do with a filing like this
Global Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Global Health Limited. Read the original for the full detail.